Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00828984 · ClinicalTrials.gov registry record · Phase 2
Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer
A Phase 2 study of Colorectal Carcinoma and Adenomatous Polyp, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 3
- Study locations
NCT00828984 is a Phase 2 study of Colorectal Carcinoma and Adenomatous Polyp that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 87 participants, below the 1,095-participant average among 53 other Colorectal Carcinoma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00828984, a Phase 2 study of Colorectal Carcinoma and Adenomatous Polyp, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 3
- Study locations
Study Summary
This randomized phase II trial studies how well macrogol 3350-based oral osmotic laxative (polyethylene glycol 3350) works in preventing cancer in patients at risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of macrogol 3350-based oral osmotic laxative may stop cancer from growing in patients who are at risk of colorectal cancer.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG macrogol 3350-based oral osmotic laxative
Study Locations (3)
Illinois
- University of Chicago - Chicago
- NorthShore University HealthSystem-Evanston Hospital - Evanston
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2009-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00828984
The ClinicalTrials.gov registry entry for NCT00828984 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,095-participant average among 53 other Colorectal Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00828984 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00828984 about?
NCT00828984 is a clinical study titled "Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer". This randomized phase II trial studies how well macrogol 3350-based oral osmotic laxative (polyethylene glycol 3350) works in preventing cancer in patients at risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of macrogol 3350-based oral osmot...
What is the current status of trial NCT00828984?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2009-10. Estimated completion is 2014-10.
What conditions does trial NCT00828984 study?
This clinical trial studies the following conditions: Colorectal Carcinoma, Adenomatous Polyp.
What interventions are being tested in trial NCT00828984?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), macrogol 3350-based oral osmotic laxative (DRUG).
Who is sponsoring clinical trial NCT00828984?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00828984 being conducted?
This trial has 3 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
ACTIVE NOT RECRUITING · Phase 2
-
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.